Feeling tired and difficulty sleeping are some of the most frequent and bothersome symptoms of menopause

Menopause symptoms experienced in the past week using MENQOL* EU5 countries, n= 20351.

symptoms-experienced-in-the-past-week-img

Adapted from Nappi RE, et al. Menopause 2021;28(8):875–882.
*MENQOL, Menopause-Specific QOL (questionnaire to assess QOL and impact of menopause symptoms)2

VEOZA works around the clock to help reduce the impact of night sweats and hot flushes on your patients nights and days2

vms-flushes-percentage-compare-img

VMS: Vasomotor Symptoms, also known as night sweats and hot flushes.
Reduction from baseline was a mean of 2.9 for night-time VMS and a mean of 4.1 for daytime VMS. Data are from a prespecified pooled analysis of the Phase 3 studies SKYLIGHT 1 and 2.

Quality of Life improvement

Sleep problems during menopause can lead to substantial impact on quality of life and ability to function the next day7. This is often measured using MENQOL, the Menopause-Specific QOL questionnaire to assess QOL and impact of menopause symptoms2.

 

With Veoza, there was a greater improvement in QoL (MENQOL) compared with placebo4,5,6

Mean change in MENQOL Total Scorea from Baseline to Week 12 in SKYLIGHT 1&2 Pooled Analysis

pooled-favours-img

aComprises all 4 domains and 29 items. Negative change indicates improvement from baseline.

Relief that works Fast and Lasts3

In 1 week, patients taking VEOZA experienced a reduction in the number of VMS episodes, which was sustained through 52 weeks5,8

daily-mean-frequency-graph

Graph produced using the FAS.5,9

Once daily dosing

The recommended dose of VEOZA is 1 tablet taken orally with or without food3

once-daily-dosing-img

 

It's time to discuss VEOZA with your patients today.

 

Fast relief of hot flushes & night sweats. 1 tablet. 1 dose. 1 per day.

References:

  1. Nappi RE, et al. Menopause 2021;28(8):875–882.
  2. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas  1996;24:161-175
  3. VEOZA Summary of Product Characteristics.
  4. Astellas. VEOZA. Data on file.
  5. Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab (Epub) 02-03-2023.
  6. Supplement to: Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet (Epub) 03-13-2023.
  7. Maki, P. M., Panay, N., & Simon, J. A. (2024). Sleep disturbance associated with the menopause. Menopause, 31(8), 724–733.
  8. Thurston RC. Vasomotor symptoms. In: Crandall CJ, Bachman GA, Faubion SS, et al., eds. Menopause Practice: A Clinician’s Guide. 6th ed. Pepper Pike, OH: The North American Menopause Society, 2019:43-55
  9. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 2023;401(10382):1091–102.

MAT-IE-VEO-2025-00044 June 25